---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-033598"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-04-17T23:59:59+00:00"
generated_at: "2026-06-03T21:32:05.879261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ABVC signs exclusive license deal with OncoX for NSCLC drug; up to $13.75M in fees + up to $12.5M royalties

## Summary
- License for ABVC's single-herb botanical extract from Maitake Mushroom (BLEX 404) for NSCLC in North America for 20 years.
- Aggregate license fee of $12.5M (cash or OncoX shares) due within 30 days of signing; additional $1.25M milestone after OncoX's next fundraising (no guarantee).
- ABVC and affiliate Rgene also entitled to 5% royalties on net sales, capped at $12.5M, post-commercial launch.
- FDA has approved IND for ABV-1519 (BLEX 404) as combination therapy with chemotherapy for NSCLC.
- OncoX is a private BVI company specializing in oncology dietary supplements; deal leverages ABVC's clinical-stage pipeline.

## SEC filing metadata
- accession: 0001213900-24-033598
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/0001213900-24-033598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/ea0203971-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-033598
- JSON: https://secwatch.observer/filing/0001213900-24-033598.json
- Plain text: https://secwatch.observer/filing/0001213900-24-033598.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) (effective 2024-04-16).
  - Action: entry
  - Agreement: license
  - Counterparty: OncoX BioPharma, Inc.
  - Value: $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share)
  - Effective: 2024-04-16
  source text: On April 16, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (" Oncox "), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Non-Small Cell Lung Cancer (the “ Licensed Products ”), within North America for 20 years (the “ Oncox Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024033598/0001213900-24-033598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.